---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-276693"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2026-06-22T11:09:59+00:00"
generated_at: "2026-06-22T11:16:23.087810+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TSC-101 Cohort C: 11/14 patients achieved complete donor chimerism; Phase 3 start planned this month

## Summary
- 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion; 2 additional patients approaching.
- ~90% manufacturing success rate (17/19) with commercial-ready process; 14/19 patients received first infusion.
- One TP53-mutated AML patient remained in complete donor chimerism 6 months post-HCT.
- TSC-101 well-tolerated; safety consistent with Cohort A; company plans to initiate Phase 3 ALLOHA-2 study this month.

## SEC filing metadata
- accession: 0001193125-26-276693
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2026-06-22T11:09:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312526276693/0001193125-26-276693-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312526276693/d103234d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-276693
- JSON: https://secwatch.observer/filing/0001193125-26-276693.json
- Plain text: https://secwatch.observer/filing/0001193125-26-276693.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.